Amylin analogs for the treatment of obesity without diabetes: present and future
Theodoros Panou,Evanthia Gouveri,Djordje S. Popovic,Nikolaos Papanas
DOI: https://doi.org/10.1080/17512433.2024.2409403
2024-10-01
Expert Review of Clinical Pharmacology
Abstract:Introduction Obesity is a pandemic, linked with increased morbidity including diabetes mellitus (DM) and certain cancer types. Amylin is a major regulatory hormone for satiation and food intake perception in humans. Amylin analogs (pramlintide and cagrilintide) are emerging as promising anti-obesity agents in non-DM subjects.
pharmacology & pharmacy
What problem does this paper attempt to address?